{"paper_id":"3def59b9-6919-43b8-bcd9-f9bee8982ad3","body_text":"Review began\n 11/02/2026 \nReview ended\n 11/14/2026 \nPublished\n 11/18/2026\n© Copyright \n2026\nJesmin et al. This is an open access article\ndistributed under the terms of the Creative\nCommons Attribution License CC-BY 4.0.,\nwhich permits unrestricted use, distribution,\nand reproduction in any medium, provided\nthe original author and source are credited.\nDOI:\n 10.7759/cureus.119919\nSurgery Versus Medical Treatment for Deep\nInfiltrating Endometriosis: A Systematic Review\nof Pain, Quality of Life, Fertility, Recurrence, and\nTreatment-Related Complications\nMosammat Shahana Jesmin \n, \nSaria Tasnim \n, \nMarjia Begum \n, \nAlauddin . \n, \nFarah Parisha Bhuiyan \n1.\n Department of Obstetrics and Gynecology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry,\nGBR \n2.\n Department of Cardiac Surgery, Dhaka Medical College and Hospital, Dhaka, BGD \n3.\n Department of Obstetrics\nand Gynecology, Kuwait Bangladesh Friendship Government Hospital, Dhaka, BGD \n4.\n Department of Pediatrics,\nNational Institute of Cancer Research and Hospital, Dhaka, BGD \n5.\n Department of Oncology, Ahsania Mission Cancer &\nGeneral Hospital, Dhaka, BGD\nCorresponding author: \nMosammat Shahana Jesmin, \njasminnhs@proton.me\nAbstract\nDeep infiltrating endometriosis (DIE) is associated with chronic pelvic pain, dysmenorrhea, deep\ndyspareunia, bowel and urinary symptoms, infertility, and impaired quality of life. Management includes\nhormonal treatment and surgery, but the comparative benefits and risks of these approaches remain\nuncertain. This review examines evidence concerning pain relief, quality of life, fertility, recurrence, and\ntreatment-related complications in women with DIE. The available literature includes a limited number of\ndirect comparisons between surgery and hormone-based treatment, together with observational surgical\ncohorts and studies comparing different surgical techniques. Both medical and surgical treatment have been\nassociated with improvement in endometriosis-related pain. Surgical cohorts also report improvements in\nquality of life and bowel function, and pregnancies have been documented after excision of deep disease.\nHowever, most postoperative studies lack a nonsurgical control group, and comparisons between surgical\ntechniques do not establish the relative effectiveness of surgery and medical treatment. Recurrence and\nclinically important bowel and urinary complications remain relevant considerations. The available evidence\ndoes not establish that surgery is universally superior to medical treatment. Management should therefore\nbe individualized according to symptoms, lesion location and extent, reproductive plans, previous\ntreatment, and the risks associated with the proposed intervention. The certainty of comparative\nconclusions is limited by the predominance of observational evidence and the inadequate recruitment of the\navailable randomized trial.\nCategories:\n Obstetrics/Gynecology\nKeywords:\n deep infiltrating endometriosis, endometriosis surgery, fertility, hormonal treatment, surgical\ncomplications\nIntroduction And Background\nEndometriosis is a chronic inflammatory disease characterized by the presence of endometrium-like tissue\noutside the uterine cavity. It may cause dysmenorrhea, chronic pelvic pain, deep dyspareunia, bowel or\nurinary symptoms, infertility, and reduced health-related quality of life. Deep infiltrating endometriosis\n(DIE), also termed deep endometriosis, refers to disease that extends into deeper pelvic tissues and may\ninvolve the uterosacral ligaments, rectovaginal septum, bowel, bladder, and ureters. The location and extent\nof these lesions influence the symptoms, anatomical distortion, and complexity of treatment \n[1-4]\n.\nSurgical treatment aims to remove endometriotic lesions and relieve associated fibrosis, adhesions, and\nanatomical distortion. Depending on the location and extent of disease, procedures may include\nlaparoscopic excision, rectal shaving, discoid excision, segmental bowel resection, bladder excision, and\nureterolysis or reconstruction \n[5]\n. Extensive disease may require a multidisciplinary team involving\ngynecologists, colorectal surgeons, urologists, radiologists, and fertility specialists. Although surgery may\nimprove pain and organ-related symptoms, it also carries risks of bowel, urinary tract, vascular,\nneurological, and other complications. Persistent symptoms and recurrence may occur despite apparently\ncomplete excision \n[6]\n.\nMedical treatment principally aims to control symptoms by suppressing hormonal stimulation of\nendometriotic tissue. Treatment options include combined hormonal contraceptives, progestogens,\nlevonorgestrel-releasing intrauterine systems, gonadotropin-releasing hormone (GnRH) agonists, and GnRH\nantagonists. These treatments avoid the immediate risks of major surgery and may provide symptom\ncontrol, although adverse effects, incomplete symptom relief, and recurrence after discontinuation can limit\ntheir effectiveness. Hormonal suppression also generally prevents attempts at spontaneous conception\nwhile treatment continues \n[7,8]\n.\n1\n2\n3\n4\n5\n \nOpen Access Review Article\nHow to cite this article\nJesmin M, Tasnim S, Begum M, et al. (November 18, 2026) Surgery Versus Medical Treatment for Deep Infiltrating Endometriosis: A Systematic\nReview of Pain, Quality of Life, Fertility, Recurrence, and Treatment-Related Complications. Cureus 18(11): e119919. \nDOI 10.7759/cureus.119919\n\nThe European Society of Human Reproduction and Embryology guideline recommends individualized\nmanagement, consideration of surgery for pain, and referral of women with deep disease to centers with\nappropriate expertise \n[9]\n. However, these recommendations do not establish that surgery is more effective\nthan medical treatment for every patient.\nDirect comparison of these approaches is challenging. Women selected for surgery may have more extensive\nanatomical disease, severe symptoms, or inadequate responses to previous medical treatment. Conversely,\nwomen receiving medical treatment may differ in their fertility intentions, comorbidities, surgical\nsuitability, and treatment preferences. The DIAMOND randomized controlled trial was designed to compare\nlaparoscopic surgery with optimized medical management for deep endometriosis, but inadequate\nrecruitment prevented a definitive comparison \n[10]\n.\nConsequently, an important evidence gap remains regarding the comparative effectiveness and safety of\nsurgery and medical treatment. Postoperative improvements reported in surgical cohorts provide useful\nclinical information but cannot independently establish superiority over medical management. This review\ntherefore examines direct comparative evidence alongside complementary primary studies reporting\noutcomes after surgery for DIE. The objective is to assess evidence concerning pain relief, quality of life,\nfertility, recurrence, and treatment-related complications while distinguishing postoperative improvement\nfrom evidence of comparative treatment effectiveness.\nReview\nMaterials and methods\nStudy Design and Reporting Framework\nThis systematic review was conducted and reported in accordance with the PRISMA 2020 statement \n[11]\n.\nThe literature-search methods were reported with reference to the PRISMA-S extension \n[12]\n. The review\nquestion, eligibility criteria, information sources, data-extraction procedures, and evidence-synthesis\nframework were established before final study selection. The review was not prospectively registered, and no\nregistration number was assigned. Formal risk-of-bias assessment was not performed.\nReview Question and Eligibility Criteria\nThe review population comprised reproductive-age women diagnosed with DIE through surgery,\nhistopathology, or appropriate imaging. Eligible interventions included surgical excision and medical\ntreatment with hormonal therapies. The primary outcome was endometriosis-associated pain, including\nchronic pelvic pain, dysmenorrhea, deep dyspareunia, and dyschezia. Secondary outcomes included\nvalidated quality-of-life measures, spontaneous pregnancy, clinical pregnancy, live birth, recurrence, repeat\nintervention, medication-related adverse effects, surgical complications, hospitalization, and cost-\neffectiveness.\nEligible study designs included randomized controlled trials, prospective comparative studies, retrospective\ncomparative cohorts, and primary observational studies reporting relevant clinical outcomes after treatment\nfor DIE. Direct comparisons between surgery and medical treatment constituted the principal evidence\ncategory. Surgical cohorts without a medical comparator were included as complementary evidence for\npostoperative outcomes but were not considered direct comparisons of treatment effectiveness. Studies\ncomparing different surgical techniques, including rectal shaving and segmental resection, were analyzed\nseparately.\nStudies involving superficial endometriosis or isolated ovarian endometriomas were excluded unless DIE-\nspecific outcomes could be extracted. Case reports, editorials, opinion articles, and studies without relevant\nclinical outcomes were excluded from the primary evidence synthesis. Systematic reviews and clinical\nguidelines were used for background information and citation searching but were not counted as primary\nstudies.\nInformation Sources and Search Strategy\nA comprehensive literature search was conducted using five electronic databases: MEDLINE through\nPubMed, Embase, Scopus, Web of Science Core Collection, and the Cochrane Central Register of Controlled\nTrials (CENTRAL). The searches covered the period from database inception to August 31, 2026. Reference\nlists of eligible primary studies and relevant systematic reviews were also examined to identify additional\npotentially eligible publications.\nThe search strategy combined controlled vocabulary, where available, with free-text terms relating to DIE,\nbowel endometriosis, rectovaginal endometriosis, surgery, excision, hormonal therapy, progestogens, and\nGnRH agonists or antagonists. Outcome-related terms included pain, quality of life, pregnancy, live birth,\nrecurrence, and complications. No lower publication-date limit was applied.\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n2\n of \n13\n\nThe following search strategy was used in PubMed: ((\"Endometriosis\"[Mesh] OR\nendometriosis[Title/Abstract] OR \"deep endometriosis\"[Title/Abstract] OR \"deep infiltrating endometriosis\"\n[Title/Abstract] OR \"bowel endometriosis\"[Title/Abstract] OR \"rectovaginal endometriosis\"[Title/Abstract])\nAND (surgery[Title/Abstract] OR surgical[Title/Abstract] OR excision[Title/Abstract] OR\nlaparoscopy[Title/Abstract] OR \"rectal shaving\"[Title/Abstract] OR \"segmental resection\"[Title/Abstract] OR\n\"medical treatment\"[Title/Abstract] OR hormonal[Title/Abstract] OR progestogen[Title/Abstract] OR\nprogestin[Title/Abstract] OR \"gonadotropin-releasing hormone\"[Title/Abstract] OR GnRH[Title/Abstract]))\nEquivalent search concepts were adapted for Embase, Scopus, Web of Science Core Collection, and\nCENTRAL. The database-specific search strategies and dates of execution were documented. Records\nretrieved from each database were recorded and incorporated into the study-selection process presented in\nthe PRISMA 2020 flow diagram.\nStudy Selection and Data Extraction\nAll records retrieved from the five databases and additional citation searching were consolidated in\nreference-management software. Duplicate records were removed before screening. Two reviewers\nindependently screened titles and abstracts against the predefined eligibility criteria. Full texts of\npotentially eligible publications were subsequently assessed independently by the same reviewers.\nDisagreements regarding study eligibility were resolved through discussion and consensus. Reasons for\nexclusion at the full-text stage were documented. Publications reporting results from the same patient\ncohort were identified and linked to avoid double-counting participants.\nData were extracted from the included studies using a structured approach. Extracted variables included\nauthor, publication year, country, study design, sample size, diagnostic criteria, lesion location, baseline\nsymptoms, previous treatment, surgical technique, medical regimen, and follow-up duration. Clinical\noutcomes included pain scores, quality-of-life measures, spontaneous and clinical pregnancy, live birth,\nrecurrence, repeat intervention, and treatment-related complications. Adjusted estimates and CIs were\nrecorded when reported in the original publications.\nRisk of Bias and Synthesis\nFormal risk-of-bias assessments using the Cochrane Risk of Bias 2 (RoB 2) tool and the Risk Of Bias In Non-\nrandomized Studies of Interventions (ROBINS-I) tool were not performed \n[13,14]\n. Accordingly, no formal\nstudy-level risk-of-bias judgments were assigned. Methodological limitations were considered descriptively,\nwith attention to potential confounding by indication, patient selection, intervention classification, missing\noutcome data, outcome measurement, and selective reporting.\nA narrative synthesis was undertaken because the included studies differed in design, disease location,\ntreatment regimen, surgical technique, and outcome definitions. Direct comparisons between surgery and\nmedical treatment were synthesized separately from uncontrolled surgical cohorts and studies comparing\ndifferent surgical techniques. Where available, original study-reported effect estimates, CIs, and p-values\nwere considered in interpreting individual findings. Meta-analysis was not performed because the available\nevidence was insufficiently homogeneous to support valid pooling. No pooled treatment-effect estimate was\ncalculated.\nResults\nA total of 2,491 records were identified through electronic database searches and additional sources. After\nremoval of 519 duplicates, 1,972 records underwent title and abstract screening. Following screening and\nfull-text eligibility assessment, eight primary studies met the inclusion criteria and were included in the\nqualitative synthesis. The identification, screening, eligibility assessment, and inclusion processes are\nsummarized in the PRISMA 2020 flow diagram (Figure \n1\n).\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n3\n of \n13\n\nFIGURE\n 1: PRISMA 2020 flow diagram of study identification, screening,\neligibility assessment, and inclusion in the systematic review.\nThe flow diagram illustrates the study selection process for the systematic review. A total of 2,491 records were\nidentified through database searches (n = 2,417) and additional sources (n = 74). After removing 519 duplicates,\n1,972 records underwent title and abstract screening, of which 1,848 were excluded. Full-text assessment was\nperformed for 124 articles, and 116 were excluded for predefined eligibility criteria. Ultimately, eight primary\nstudies were included in the qualitative synthesis.\nDIE, deep infiltrating endometriosis\nStudy Characteristics\nThe broadened evidence framework includes direct comparative studies and primary cohorts reporting\npostoperative outcomes after surgery for DIE. The direct comparison by Rezende et al. included 122 women\nwith bowel DIE treated surgically or with hormone-based therapy \n[15]\n. The DIAMOND trial was a randomized\ncomparison intended to recruit 320 participants but randomized only 18 \n[10]\n.\nComplementary surgical studies include the multicenter prospective cohort reported by Byrne et al., the\nprospective cohort of 134 women undergoing bowel surgery reported by Hudelist et al., the retrospective\ncohort of 195 women reported by Bourdel et al., and the historical series of 193 women undergoing\nrectosigmoid resection reported by Raos et al. \n[16-19]\n. Additional cohorts evaluated gastrointestinal\nfunction and long-term pain, quality of life, fertility, and recurrence after surgery \n[20,21]\n.\nThese studies contribute useful information across the review outcomes, but they do not all answer the same\ntreatment question. In particular, a postoperative improvement in a surgical cohort cannot by itself\ndemonstrate that surgery is superior to medical treatment. The characteristics and principal findings of the\nincluded studies are summarized in Table \n1\n.\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n4\n of \n13\n\nStudy\nDesign and population\nTreatment or\nexposure\nMain outcomes and findings\nEvidence\ncategory\nCooper et\nal. \n[10]\nMulticenter randomized trial; 18\nparticipants randomized\nPlanned surgery\nversus optimized\nmedical management\nRecruitment and follow-up insufficient to\nestimate comparative effectiveness\nDirect\ncomparison,\ninconclusive\nRezende\net al. \n[15]\nRetrospective cohort; 122 women with\nbowel DIE\nSurgery (n = 61)\nversus hormone-\nbased treatment (n =\n61)\nBoth groups improved; surgery was\nassociated with greater and more sustained\nimprovement in selected pain symptoms\nDirect\ncomparison\nByrne et\nal. \n[16]\nMulticenter prospective cohort; 4,721\nplanned excisions among 5,162 women\nwith rectovaginal endometriosis\nLaparoscopic\nexcision\nPain and quality of life improved; overall\ncomplication incidence 6.8%\nSurgical\noutcomes\nHudelist et\nal. \n[17]\nProspective cohort; 134 women with\ncolorectal DIE\nDisk resection versus\nsegmental resection\nBoth procedures improved pain and quality\nof life; pregnancy outcomes reported; serious\ncomplications in 5.9%\nSurgical\ntechnique\ncomparison\nBourdel et\nal. \n[18]\nRetrospective cohort; 195 women with\nlarge rectovaginal nodules\nRectal shaving\nversus colorectal\nresection\nPain improved in both groups; pregnancy\nrates 73% and 69%; major complications\nmore frequent after resection\nSurgical\ntechnique\ncomparison\nRaos et\nal. \n[19]\nHistorical case series; 193 women with\nrectosigmoid DIE and pregnancy\nintention\nRectosigmoid\nresection\nPregnancy rate 60.6%; live-birth rate 53.9%\nFertility\noutcomes\nafter\nsurgery\nDior et al.\n[20]\nProspective cohort; 149 patients with\ndeep endometriosis\nSurgery\nBowel function and bowel-related quality of\nlife improved\nSurgical\noutcomes\nMeuleman\net al. \n[21]\nRetrospective cohort; 56 patients with\ndeep colorectal endometriosis\nMultidisciplinary\nlaparoscopic excision\nPain, quality of life, and sexual activity\nimproved; recurrence and pregnancy\noutcomes reported\nSurgical\noutcomes\nTABLE\n 1: Primary studies contributing evidence on DIE outcomes.\nThis table summarizes the study designs, populations, interventions or exposures, principal clinical outcomes, and evidence categories of the eight\nincluded studies investigating surgical and medical management of DIE. The studies evaluated pain relief, quality of life, bowel function, fertility outcomes,\npregnancy rates, recurrence, and treatment-related complications. Evidence included direct comparisons between surgery and medical treatment,\ncomparisons of surgical techniques, and observational studies reporting outcomes following surgical intervention. The heterogeneity in study design,\npopulation characteristics, and outcome measures was considered when interpreting the findings.\nDIE, deep infiltrating endometriosis\nDirect Comparison of Surgery and Medical Treatment\nRezende et al. conducted a retrospective cohort study of 122 women with bowel DIE, with 61 women\nreceiving surgery and 61 receiving hormone-based treatment \n[15]\n. Both groups experienced improvement in\npain symptoms. Surgery was associated with greater and more sustained improvement in chronic pelvic\npain, dyschezia, and deep dyspareunia. However, surgery was undertaken because of poor pain control, and\nsome women received hormonal suppression after surgery. The results therefore reflect selected treatment\npathways and cannot be interpreted as an unbiased causal comparison.\nThe DIAMOND trial was designed to compare early planned laparoscopic surgery, with or without adjuvant\nmedical treatment, against optimized medical management alone \n[10]\n. The primary outcome was the pain\ndomain of the Endometriosis Health Profile-30 at 18 months, with a planned economic evaluation. Although\n377 patients were screened and 103 were eligible, only 18 participants were randomized against a planned\nsample of 320. No participant reached the primary 18-month outcome. The trial could not establish\ncomparative clinical effectiveness or cost-effectiveness. Its failure to demonstrate a difference should not be\ninterpreted as evidence that the two treatments are equivalent. The outcome-specific evidence and its\nprincipal limitations are summarized in Table \n2\n.\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n5\n of \n13\n\nOutcome\nEvidence identified\nInterpretation\nPrincipal limitation\nPain relief\nRezende et al. \n[15]\n and\nsurgical cohorts\nBoth medical and surgical treatment were associated\nwith improvement in pain; surgical cohorts reported\npostoperative improvement\nConfounding by indication and\nlimited direct comparative\nevidence\nQuality of life\nByrne et al. \n[16]\n, Dior et al.\n[20]\n, Meuleman et al. \n[21]\nImprovement following surgery was reported across\ndisease-specific and general quality-of-life measures\nLimited direct comparison with\nmedical treatment\nFertility\nHudelist et al. \n[17]\n, Bourdel et\nal. \n[18]\n, Raos et al. \n[19]\nPregnancy and live birth were reported following surgery\nin selected patients\nNo reliable evidence of\nsuperiority over nonsurgical\nmanagement\nRecurrence\nBourdel et al. \n[18]\n, Meuleman\net al. \n[21]\nRecurrence and repeat intervention were reported, with\nestimates varying by definition and follow-up\nHeterogeneous definitions and\nlimited comparative evidence\nSurgical\ncomplications\nByrne et al. \n[16]\n, Hudelist et\nal. \n[17]\n, Bourdel et al. \n[18]\n,\nRaos et al. \n[19]\nComplication risk varied according to procedure and\ndisease extent\nDifferences in case mix and\ncomplication definitions\nMedical\nadverse\neffects\nExternal hormonal-treatment\nliterature\nHormonal treatment may cause treatment-related\nadverse effects that influence tolerability\nNot adequately evaluated in\nthe included comparative\nstudies\nCost-\neffectiveness\nDIAMOND trial \n[10]\nComparative cost-effectiveness remained unresolved\nInsufficient recruitment and\nabsence of completed primary\noutcome data\nTABLE\n 2: Summary of evidence for clinical outcomes following surgical and medical treatment of\nDIE.\nThis table summarizes the evidence relating to pain relief, quality of life, fertility, recurrence, surgical complications, medical adverse effects, and cost-\neffectiveness in DIE. Evidence from the eight included primary studies is distinguished from external contextual literature. Direct comparisons between\nsurgery and medical treatment are presented separately from observational surgical outcomes and surgical technique comparisons. The heterogeneity of\nstudy designs, populations, and outcome definitions limits definitive comparisons between treatment approaches.\nDIE, deep infiltrating endometriosis\nPain Outcomes\nDirect comparative evidence regarding pain relief was primarily provided by Rezende et al. \n[15]\n. Both the\nsurgical and hormone-based treatment groups experienced improvement in pain symptoms. However,\nsurgery was associated with greater and more sustained improvement in selected symptoms, including\nchronic pelvic pain, dyschezia, and deep dyspareunia. As treatment allocation was nonrandomized, these\nfindings may have been influenced by differences in baseline symptoms, treatment selection, and\npostoperative hormonal suppression.\nThe DIAMOND trial was designed to compare early planned laparoscopic surgery, with or without adjuvant\nmedical treatment, against optimized medical management alone \n[10]\n. Although 377 patients were screened\nand 103 were eligible, only 18 participants were randomized. No participant reached the primary 18-month\noutcome. Consequently, the trial could not establish comparative clinical effectiveness, and its findings\ncannot be interpreted as evidence of equivalence between surgery and medical treatment.\nPostoperative improvements in pain were also reported in several surgical cohorts. In the multicenter\nprospective cohort reported by Byrne et al., women undergoing planned laparoscopic excision experienced\nsignificant reductions in premenstrual, menstrual, and noncyclical pelvic pain, deep dyspareunia, dyschezia,\nlow back pain, and bladder pain at six months \n[16]\n. Improvements were generally maintained at two years,\nalthough improvement in voiding difficulty was an exception.\nBourdel et al. reported significant reductions in pelvic pain and dysmenorrhea following both rectal shaving\nand colorectal resection \n[18]\n. Mean pelvic pain scores decreased from 5.5 to 2.3 in the rectal-shaving group\nand from 7.3 to 2.0 in the colorectal-resection group. Meuleman et al. also reported improvements in\ngynecological pain following multidisciplinary laparoscopic excision \n[21]\n. These findings indicate\npostoperative symptom improvement but do not establish the superiority of surgery over medical treatment.\nBowel and Urinary Function\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n6\n of \n13\n\nBowel and urinary outcomes were reported mainly in observational surgical cohorts. In the Byrne et al.\nmulticenter cohort, improvements were observed in bowel-related symptoms, including dyschezia,\nfollowing laparoscopic excision \n[16]\n. Bladder pain also decreased during follow-up, although improvement\nin voiding difficulty was not maintained to the same extent as other reported symptoms.\nDior et al. prospectively followed 149 patients after surgery for deep endometriosis \n[20]\n. Mean bowel pattern\nscores improved from 4.8 before surgery to 4.2 at 12 months. The impact of bowel symptoms on quality of\nlife improved from 5.5 before surgery to 4.4 at six months. Patients with direct lower gastrointestinal\ninvolvement and poorer baseline bowel function tended to experience greater improvement.\nThese findings suggest that surgery may improve bowel symptoms and bowel-related quality of life in\nselected patients. However, the absence of nonsurgical control groups in these cohorts limits conclusions\nabout the comparative effectiveness of surgery and medical treatment.\nQuality-of-Life Outcomes\nImprovement in quality of life following surgery was reported in the Byrne, Dior, and Meuleman cohorts\n[16,20,21]\n. In the Byrne et al. study, median global quality-of-life scores increased from 55/100 before\nsurgery to 80/100 at six months, with improvements maintained through two years \n[16]\n. Analgesic use also\ndecreased, including opioid use from 28.1% before surgery to 16.1% at six months.\nDior et al. reported improvement in bowel-related quality of life following surgery, with the mean bowel-\nimpact score decreasing from 5.5 before surgery to 4.4 at six months \n[20]\n. Meuleman et al. also reported\nsignificant improvements in quality of life and sexual activity after multidisciplinary laparoscopic excision\n[21]\n.\nAlthough these studies consistently reported postoperative improvement, differences in assessment\ninstruments, follow-up periods, patient characteristics, and surgical procedures prevented direct\ncomparison of the magnitude of benefit across studies. Most of these findings were derived from\nuncontrolled surgical cohorts and therefore do not demonstrate that surgery provides greater quality-of-life\nimprovement than medical treatment.\nFertility and Pregnancy Outcomes\nFertility evidence primarily comes from surgical cohorts rather than direct comparisons with medical\ntreatment. In the prospective cohort of 134 women with colorectal DIE reported by Hudelist et al., 61\nwomen had a history of infertility. Among these, 26 conceived spontaneously and 13 conceived through in\nvitro fertilization, corresponding to an overall pregnancy rate of 63.4% in that subgroup \n[17]\n. The study\ncompared disk resection with segmental resection, not surgery with medical treatment.\nBourdel et al. reported pregnancy rates of 73% after rectal shaving and 69% after colorectal resection among\nwomen seeking pregnancy \n[18]\n. These rates were not significantly different between the surgical techniques.\nIn the historical cohort of 193 women undergoing rectosigmoid resection, Raos et al. reported postoperative\npregnancy and live-birth rates of 60.6% and 53.9%, respectively \n[19]\n. Pregnancy occurred spontaneously in\n20.2% of the full cohort, while the remainder of pregnancies involved intrauterine insemination or assisted\nreproductive technology.\nThese observations demonstrate that pregnancy and live birth are possible after surgery for bowel DIE. They\ndo not establish that surgery improves fertility compared with expectant management or medical treatment,\nbecause the studies lacked an appropriate direct comparison. Fertility outcomes depend on age, ovarian\nreserve, tubal function, other infertility factors, reproductive intention, and use of assisted reproductive\ntechnology.\nRecurrence and Repeat Intervention\nRecurrence outcomes varied by study and definition. Meuleman et al. reported cumulative recurrence of 2%\nat one year and 7% at four years after multidisciplinary laparoscopic excision \n[21]\n. In the Bourdel et al.\ncohort, 13 women in the rectal-shaving group underwent repeat surgery for suspected recurrence, compared\nwith none in the colorectal-resection group; the difference was not statistically significant \n[18]\n. The authors\nnoted that the repeat operations did not all confirm recurrent endometriosis.\nThese results should not be interpreted as establishing a universal recurrence rate or as demonstrating that\none surgical technique consistently prevents recurrence better than another. Differences in lesion extent,\noperative approach, postoperative hormonal treatment, follow-up duration, and the definition of recurrence\nlimit comparisons. They also do not establish whether surgery prevents recurrence more effectively than\nmedical treatment. The study characteristics and reported clinical outcomes are presented in Table \n3\n.\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n7\n of \n13\n\nStudy\nSample and design\nOutcome\nassessed\nReported findings\nInterpretation\nRezende\net al. \n[15]\n122 women with bowel\nDIE; retrospective\ncomparative cohort\nChronic pelvic pain,\ndysmenorrhea,\ndeep dyspareunia,\ndyschezia, and\ndysuria\nBoth surgery and hormone-based\ntreatment improved pain; surgery was\nassociated with greater and more\nsustained improvement in selected\nsymptoms\nDirect comparative evidence,\nlimited by nonrandomized\ntreatment allocation and\npossible confounding\nByrne et\nal. \n[16]\n5,162 women with\nrectovaginal endometriosis\nacross 51 specialist\ncenters; multicenter\nprospective cohort\nPelvic pain, bowel\nand urinary\nsymptoms,\nanalgesic use, and\nquality of life\nPain and quality of life improved\nfollowing planned laparoscopic\nexcision, with benefits generally\nmaintained during follow-up\nLarge multicenter evidence of\npostoperative improvement, but\nno medical-treatment control\ngroup\nHudelist et\nal. \n[17]\n134 women with colorectal\nDIE; prospective cohort\nPain, fertility, and\ncomplications\nPain outcomes and pregnancies were\nassessed after disk or segmental bowel\nresection\nUseful for surgical outcomes\nand technique comparisons,\nnot direct comparison with\nhormonal treatment\nBourdel et\nal. \n[18]\n195 women with large\nrectovaginal nodules;\nretrospective cohort\nPain, pregnancy,\nrecurrence, and\ncomplications\nPain improved after rectal shaving and\ncolorectal resection; pregnancy was\nreported in women seeking conception\nTechnique-specific\nobservational evidence subject\nto selection bias\nRaos et\nal. \n[19]\n193 women undergoing\nrectosigmoid resection;\nhistorical cohort\nPregnancy and live\nbirth\nPostoperative pregnancies and live\nbirths were reported in a cohort with\nfertility intentions\nDemonstrates reproductive\noutcomes after surgery but\ndoes not establish a fertility\nbenefit over nonsurgical\nmanagement\nDior et al.\n[20]\n149 patients; prospective\ncohort\nBowel function and\nbowel-related\nquality of life\nBowel symptoms and their impact on\nquality of life improved following surgery\nSupports postoperative\nfunctional improvement;\ncomparative effectiveness\nremains uncertain\nMeuleman\net al. \n[21]\n56 patients; retrospective\ncohort\nPain, quality of life,\nsexual activity,\nrecurrence, and\npregnancy\nImprovements in pain and quality of life\nwere reported after multidisciplinary\nlaparoscopic excision\nSmall observational cohort with\nlimited ability to establish long-\nterm comparative effects\nTABLE\n 3: Study characteristics and reported pain, quality-of-life, and fertility outcomes following\ntreatment of DIE.\nThis table summarizes the clinical outcomes reported in seven studies evaluating surgical management of DIE. The outcomes include pelvic pain,\ndysmenorrhea, dyspareunia, bowel and urinary symptoms, quality of life, fertility, pregnancy, live birth, recurrence, and postoperative complications.\nCooper et al. \n[10]\n was not included in this table because the DIAMOND trial did not produce completed primary outcome data. The predominantly\nobservational nature of the included studies limits conclusions regarding the comparative effectiveness of surgery and medical treatment.\nDIE, deep infiltrating endometriosis\nTreatment-Related Complications\nIn the Byrne et al. cohort, the overall incidence of complications after planned laparoscopic excision was\n6.8% \n[16]\n. Gastrointestinal complications, including enterotomy, anastomotic leak, or fistula, occurred in\n1.1% of procedures, while urinary tract complications, including ureteric or bladder injury or leakage,\noccurred in 1.0%.\nIn the Bourdel et al. cohort, major complications occurred in 4% of women undergoing rectal shaving and\n26% of those undergoing colorectal resection, a statistically significant difference \n[18]\n. The comparison was\nobservational, and the resection group was small; the findings may therefore reflect differences in disease\nseverity and surgical indication as well as procedure-related risk.\nHudelist et al. reported serious complications classified as Clavien-Dindo grades III-IV in 5.9% of the 134\nwomen undergoing disk or segmental bowel resection, with no statistically significant difference between\nthe two surgical groups \n[17]\n. Raos et al. reported grade III complications in 16.6% of the 193 women\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n8\n of \n13\n\nundergoing rectosigmoid resection \n[19]\n. These estimates should not be compared directly because patient\npopulations, definitions, procedures, and reporting methods differed.\nMedical treatment also has potential harms, including irregular bleeding, mood-related symptoms, sexual\nadverse effects, and drug-specific hypoestrogenic or bone-related effects. The available direct comparative\nevidence does not provide a sufficiently standardized basis to determine the overall safety superiority of\nsurgery or medical treatment.\nDiscussion\nPrincipal Findings\nThe expanded evidence base provides a broader view of outcomes following surgery for DIE than direct\ncomparative studies alone. Observational cohorts consistently report improvement in pain and quality of\nlife after surgical excision, while fertility studies document pregnancies and live births after surgery.\nHowever, direct comparative evidence remains insufficient to establish whether surgery is superior to\nmedical treatment across all clinical outcomes.\nThe distinction between direct and indirect evidence is fundamental. A before-and-after surgical cohort can\nshow that symptoms improved following an operation, but it cannot determine how much improvement\nwould have occurred with medical therapy, expectant management, or changes in concomitant treatment.\nSimilarly, comparisons between rectal shaving and segmental resection address the choice of surgical\ntechnique rather than the decision between surgery and medical treatment.\nPain and Quality of Life\nThe direct comparative cohort by Rezende et al. suggests that surgery may provide more sustained relief of\nselected pain symptoms in women with bowel DIE \n[15]\n. The large prospective cohort by Byrne et al. provides\ncomplementary evidence that pain, bowel and urinary symptoms, analgesic use, and quality of life can\nimprove after laparoscopic excision \n[16]\n.\nNevertheless, pain is multidimensional, and symptom improvement does not necessarily indicate complete\ndisease eradication. Persistent pain may be associated with residual lesions, pelvic floor dysfunction,\nneuropathic mechanisms, or central sensitization. Treatment decisions should therefore consider the\nspecific symptom pattern, anatomical findings, previous treatment response, and patient priorities \n[22,23]\n.\nThe observed improvement in quality of life after surgery is clinically important, but the absence of robust\ndirect comparisons limits claims of superiority over medical therapy. Future studies should use validated\ninstruments, such as the Endometriosis Health Profile-30 \n[24]\n, and report between-group differences with\nCIs at prespecified follow-up times.\nFertility Considerations\nSurgical cohorts show that pregnancy is achievable after treatment of rectosigmoid DIE. However,\npostoperative pregnancy rates cannot be interpreted as proof that surgery improves fertility compared with\nmedical management or expectant treatment. Fertility studies are particularly vulnerable to selection bias\nbecause they include women who intend to conceive and may subsequently use assisted reproductive\ntechnology.\nFertility-related decisions should account for age, ovarian reserve, tubal status, previous operations, lesion\nlocation, and other infertility factors. Surgery involving bowel or urinary tract structures also carries risks\nthat must be balanced against anticipated benefits. Hormonal suppression may be useful for symptom\ncontrol in women not seeking immediate pregnancy, but it generally prevents conception attempts while\ntreatment continues \n[7,9,25]\n.\nRecurrence and Repeat Treatment\nRecurrence should be separated into recurrent symptoms, imaging-confirmed lesions, confirmed disease at\nrepeat surgery, and the need for additional treatment. These outcomes are not interchangeable. Some\nwomen undergo repeat intervention for pain without histologically confirmed recurrence, while others may\nhave recurrent disease without undergoing another operation.\nThe available surgical cohorts show that recurrence and repeat intervention remain possible, but do not\nprovide a reliable direct comparison with medical treatment. Postoperative hormonal suppression may be\nappropriate for selected women who are not seeking immediate pregnancy, although its effect must be\ndistinguished from the effect of surgery itself.\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n9\n of \n13\n\nComplications and Treatment Selection\nSurgical risk varies substantially according to the organs involved, the extent of fibrosis, the need for bowel\nor urinary tract reconstruction, patient comorbidities, and specialist expertise. The large multicenter cohort\ndemonstrates that surgery can be associated with improved symptoms and quality of life, but\ngastrointestinal and urinary tract complications remain important considerations \n[16]\n.\nThe higher complication rate observed after colorectal resection than after rectal shaving in the Bourdel et\nal. cohort should be interpreted cautiously because the choice of procedure is influenced by lesion extent\nand depth \n[18]\n. More extensive disease may require more extensive surgery, and observational comparisons\ncannot completely separate procedural effects from differences in the underlying disease.\nMedical treatment avoids immediate operative risks but has its own adverse effects and may require\nprolonged use or repeated treatment changes. The available evidence does not establish that either strategy\nis uniformly safer. Shared decision-making should explain both the potential benefits and the risks of each\napproach.\nStrengths and Limitations\nThis systematic review has several strengths. It synthesizes evidence from eight primary studies addressing\nclinically important outcomes of DIE, including pain, quality of life, bowel function, fertility, recurrence,\nand treatment-related complications. The literature search covered five major electronic databases: PubMed,\nEmbase, Scopus, Web of Science Core Collection, and CENTRAL. Reference lists of relevant publications\nwere also examined to identify additional eligible studies. Two reviewers independently screened titles,\nabstracts, and full-text articles, with disagreements resolved through discussion and consensus.\nFurthermore, the review distinguishes direct comparisons between surgery and medical treatment from\nobservational surgical cohorts and studies comparing different surgical techniques. This distinction is\nimportant because postoperative improvement in an uncontrolled surgical cohort does not establish the\nsuperiority of surgery over medical treatment.\nThe included studies had several methodological limitations that affected the certainty of the findings.\nThese included nonrandomized treatment allocation, confounding by indication, limited direct comparisons\nwith medical management, and differences in disease severity, lesion location, and surgical techniques.\nWomen selected for surgery may have had more severe symptoms, extensive disease, or inadequate\nresponses to previous medical treatment, whereas those receiving medical treatment may have differed in\nreproductive intentions, disease characteristics, or suitability for surgery. These differences may have\ninfluenced the observed outcomes independently of the treatment received. Variations in outcome\ndefinitions and follow-up duration further limited comparisons of recurrence, fertility, and complications.\nIn particular, pregnancy, clinical pregnancy, and live birth represent distinct reproductive outcomes, while\nsymptomatic recurrence and recurrence requiring repeat surgery are not interchangeable endpoints.\nInsufficient recruitment in the available randomized controlled trial also restricted conclusions regarding\ncomparative effectiveness. The principal methodological limitations and their implications for\ninterpretation are summarized in Table \n4\n.\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n10\n of \n13\n\nMethodological\nissue\nHow it affects the evidence\nImplication for this review\nConfounding by\nindication\nWomen selected for surgery may have more severe\nsymptoms, extensive lesions, or inadequate response\nto medical treatment\nDifferences between treatment groups may reflect baseline\ndifferences as well as treatment effects\nNonrandomized\ntreatment\nallocation\nTreatment selection may be influenced by clinician\njudgment, patient preferences, fertility plans, and\nsurgical suitability\nObservational associations should not be interpreted as\ncausal effects\nAbsence of a\nmedical control\ngroup\nSurgical cohorts commonly compare symptoms before\nand after surgery without a nonsurgical comparator\nPostoperative improvement does not establish superiority\nover medical treatment\nVariation in lesion\nlocation\nBowel, bladder, ureteric, and rectovaginal disease have\ndifferent clinical consequences and surgical\nrequirements\nOutcomes should be stratified by lesion location where\ndata permit\nDifferences in\nsurgical technique\nRectal shaving, discoid excision, and segmental\nresection are not interchangeable procedures\nComparisons between techniques should remain separate\nfrom surgery-versus-medical-treatment comparisons\nConcomitant\nhormonal\nsuppression\nPostoperative medication may contribute to symptom\ncontrol or recurrence prevention\nStudies should distinguish surgery alone from surgery\ncombined with postoperative hormonal treatment\nInconsistent\noutcome\ndefinitions\nSymptom recurrence, radiological recurrence, repeat\nsurgery, and treatment resumption measure different\noutcomes\nRecurrence results should not be combined without\ncompatible definitions\nHeterogeneous\nfertility outcomes\nSpontaneous pregnancy, assisted reproduction, clinical\npregnancy, and live birth are distinct endpoints\nFertility outcomes should be reported separately and\ninterpreted in light of reproductive intention\nVariable follow-up\nduration\nShort follow-up may miss recurrence or late\ncomplications\nLong-term outcomes require adequate and clearly reported\nfollow-up\nInadequately\npowered\nrandomized\nevidence\nThe DIAMOND trial did not recruit enough participants\nto establish comparative effectiveness\nThe lack of a definitive randomized result is uncertainty, not\nproof of equivalent treatment effects\nIncomplete search\nverification\nUnverified database searches may miss eligible studies\nFinal study counts, risk-of-bias assessments, and the\nPRISMA flow diagram must await completion of the search\nand screening process\nTABLE\n 4: Methodological limitations and their implications for interpreting evidence on surgical\nversus medical treatment of DIE.\nThis table summarizes the principal methodological limitations considered when interpreting the evidence on surgical and medical management of DIE.\nThe limitations relate to treatment selection, study design, disease characteristics, surgical techniques, concomitant treatment, outcome definitions, fertility\nreporting, follow-up duration, and completeness of outcome data. These issues were considered descriptively during the narrative synthesis. Formal\nstudy-level risk-of-bias assessments using the Cochrane RoB 2 tool and ROBINS-I were not performed.\nDIE, deep infiltrating endometriosis; RoB 2, Risk of Bias 2; ROBINS-I, Risk Of Bias In Non-randomized Studies of Interventions\nThe systematic review itself also has limitations. Although the study-selection process followed the PRISMA\n2020 framework \n[11]\n, formal study-level risk-of-bias assessments using the Cochrane RoB 2 tool \n[13]\n and\nROBINS-I \n[14]\n were not performed. No formal GRADE assessment of certainty of evidence was undertaken.\nConsequently, methodological limitations were considered descriptively rather than through formal risk-of-\nbias classifications. In addition, the included studies differed in design, populations, disease characteristics,\ninterventions, surgical techniques, and outcome measurements. This heterogeneity prevented meaningful\nquantitative pooling, and a narrative synthesis was therefore undertaken without calculating pooled\ntreatment-effect estimates.\nOverall, these limitations restrict the certainty of conclusions regarding the comparative effectiveness of\nsurgery and medical treatment for DIE. The findings should be interpreted as a synthesis of the available\ncomparative and observational evidence rather than definitive evidence that either treatment strategy is\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n11\n of \n13\n\nuniversally superior. Treatment decisions should be individualized according to symptom severity,\nanatomical disease extent, reproductive plans, previous treatment response, and the potential benefits and\nrisks of each approach.\nFuture Research Directions\nFuture research should prioritize adequately powered multicenter randomized controlled trials comparing\nsurgical excision with optimized medical treatment in women with DIE. Such studies should use clearly\ndefined eligibility criteria, standardized treatment protocols, and validated outcome measures, including\npain scores and the Endometriosis Health Profile-30. Prespecified follow-up intervals should permit\nassessment of both short-term symptom improvement and long-term recurrence.\nStudies should also report fertility outcomes separately, distinguishing spontaneous conception, assisted\nreproductive technology, clinical pregnancy, and live birth. Surgical complications should be classified using\nstandardized systems, with separate reporting of bowel, urinary, vascular, and neurological complications.\nLonger follow-up is required to assess recurrence and repeat intervention reliably.\nFuture comparative studies should address baseline disease severity, lesion location, previous treatment,\nfertility intention, and concomitant postoperative hormonal therapy. Reporting adjusted effect estimates\nwith 95% CIs would improve interpretation of treatment differences and reduce the risk of over-interpreting\nuncontrolled postoperative improvements.\nConclusions\nSurgery for DIE is associated with improvements in pain, bowel function, and quality of life, with\npregnancies and live births reported in selected women. However, treatment-related complications remain\nimportant, and a fertility benefit over medical or expectant management has not been established. Direct\ncomparative evidence is limited, and the available randomized trial was inconclusive because of inadequate\nrecruitment. Therefore, surgery cannot be considered universally superior to medical treatment.\nManagement should be individualized according to symptoms, anatomical disease extent, reproductive\nplans, previous treatment response, and the risks associated with each approach.\nAdditional Information\nAuthor Contributions\nAll authors have reviewed the final version to be published and agreed to be accountable for all aspects of the\nwork.\nConcept and design:\n  \nMosammat Shahana Jesmin, Saria Tasnim, Marjia Begum, Alauddin ., Farah Parisha\nBhuiyan\nAcquisition, analysis, or interpretation of data:\n  \nMosammat Shahana Jesmin\nDrafting of the manuscript:\n  \nMosammat Shahana Jesmin, Saria Tasnim, Alauddin .\nCritical review of the manuscript for important intellectual content:\n  \nMosammat Shahana Jesmin,\nMarjia Begum, Farah Parisha Bhuiyan\nSupervision:\n  \nMosammat Shahana Jesmin, Farah Parisha Bhuiyan\nDisclosures\nAI use statement:\n The authors used ChatGPT (GPT-6; OpenAI, San Francisco, CA, USA) as follows:\nlanguage polishing, structure or formatting in Introduction and Discussion. The AI-generated content was\nmanually reviewed by cross-checking factual statements, clinical findings, and statistical data against the\noriginal studies and available source publications. Sample sizes, study characteristics, outcome measures,\nand reported statistical values were checked for consistency. References were verified using original journal\narticles, DOI links, and PubMed records, wherever available. Inaccuracies, unsupported claims, and\ninconsistencies were corrected, and the final manuscript was reviewed to ensure scientific accuracy and\nappropriate interpretation. The authors confirm that they have reviewed and verified all AI-assisted content\nand take full responsibility for the work. \nConflicts of interest:\n In compliance with the ICMJE uniform\ndisclosure form, all authors declare the following: \nPayment/services info:\n All authors have declared that no\nfinancial support was received from any organization for the submitted work. \nFinancial relationships:\n All\nauthors have declared that they have no financial relationships at present or within the previous three years\nwith any organizations that might have an interest in the submitted work. \nOther relationships:\n All authors\nhave declared that there are no other relationships or activities that could appear to have influenced the\nsubmitted work.\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n12\n of \n13\n\nReferences\n1\n. \nMartire FG, Giorgi M, D'Abate C, et al.: \nDeep infiltrating endometriosis in adolescence: early diagnosis and\npossible prevention of disease progression\n. J Clin Med. 2024, 13:550. \n10.3390/jcm13020550\n2\n. \nZondervan KT, Becker CM, Missmer SA: \nEndometriosis\n. N Engl J Med. 2020, 382:1244-56.\n10.1056/NEJMra1810764\n3\n. \nRajesh S, Mehmeti A, Smith-Walker T, Kendall B: \nDiagnosis and management of endometriosis: summary\nof updated NICE guidance\n. BMJ. 2025, 388:q2782. \n10.1136/bmj.q2782\n4\n. \nKoninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ: \nSuggestive evidence that pelvic\nendometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic\npain\n. Fertil Steril. 1991, 55:759-65. \n10.1016/s0015-0282(16)54244-7\n5\n. \nDonnez O, Roman H: \nChoosing the right surgical technique for deep endometriosis: shaving, disc excision,\nor bowel resection?\n. Fertil Steril. 2017, 108:931-42. \n10.1016/j.fertnstert.2017.09.006\n6\n. \nUgwumadu L, Chakrabarti R, Williams-Brown E, et al.: \nThe role of the multidisciplinary team in the\nmanagement of deep infiltrating endometriosis\n. Gynecol Surg. 2017, 14:15. \n10.1186/s10397-017-1018-0\n7\n. \nEndometriosis: diagnosis and management\n. (2017). Accessed: October 30, 2026:\nhttps://www.nice.org.uk/guidance/ng73\n.\n8\n. \nD'Alterio MN, D'Ancona G, Raslan M, Tinelli R, Daniilidis A, Angioni S: \nManagement challenges of deep\ninfiltrating endometriosis\n. Int J Fertil Steril. 2021, 15:88-94. \n10.22074/IJFS.2020.134689\n9\n. \nBecker CM, Bokor A, Heikinheimo O, et al.: \nESHRE guideline: endometriosis\n. Hum Reprod Open. 2022,\n2022:hoac009. \n10.1093/hropen/hoac009\n10\n. \nCooper K, Constable L, Vadiveloo T, et al.: \nClinical and cost-effectiveness of medical management versus\nsurgery for deep infiltrating endometriosis: synopsis from the DIAMOND RCT\n. Health Technol Assess. 2026,\n30:437-64. \n10.3310/GJKC5715\n11\n. \nPage MJ, McKenzie JE, Bossuyt PM, et al.: \nThe PRISMA 2020 statement: an updated guideline for reporting\nsystematic reviews\n. BMJ. 2021, 372:n71. \n10.1136/bmj.n71\n12\n. \nRethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB: \nPRISMA-S: an extension\nto the PRISMA Statement for Reporting Literature Searches in Systematic Reviews\n. Syst Rev. 2021, 10:39.\n10.1186/s13643-020-01542-z\n13\n. \nSterne JA, Savović J, Page MJ, et al.: \nRoB 2: a revised tool for assessing risk of bias in randomised trials\n. BMJ.\n2019, 366:l4898. \n10.1136/bmj.l4898\n14\n. \nSterne JA, Hernán MA, Reeves BC, et al.: \nROBINS-I: a tool for assessing risk of bias in non-randomised\nstudies of interventions\n. BMJ. 2016, 355:i4919. \n10.1136/bmj.i4919\n15\n. \nRezende GP, Venturini MC, Kawagoe LN, Yela Gomes DA, Benetti-Pinto CL: \nSurgery vs. hormone-based\ntreatment for pain control in deep infiltrating endometriosis: a retrospective cohort study\n. Curr Med Res\nOpin. 2022, 38:641-7. \n10.1080/03007995.2022.2031940\n16\n. \nByrne D, Curnow T, Smith P, Cutner A, Saridogan E, Clark TJ: \nLaparoscopic excision of deep rectovaginal\nendometriosis in BSGE endometriosis centres: a multicentre prospective cohort study\n. BMJ Open. 2018,\n8:e018924. \n10.1136/bmjopen-2017-018924\n17\n. \nHudelist G, Aas-Eng MK, Birsan T, et al.: \nPain and fertility outcomes of nerve-sparing, full-thickness disk or\nsegmental bowel resection for deep infiltrating endometriosis—a prospective cohort study\n. Acta Obstet\nGynecol Scand. 2018, 97:1438-46. \n10.1111/aogs.13436\n18\n. \nBourdel N, Comptour A, Bouchet P, et al.: \nLong-term evaluation of painful symptoms and fertility after\nsurgery for large rectovaginal endometriosis nodule: a retrospective study\n. Acta Obstet Gynecol Scand. 2018,\n97:158-67. \n10.1111/aogs.13260\n19\n. \nRaos M, Mathiasen M, Seyer-Hansen M: \nImpact of surgery on fertility among patients with deep infiltrating\nendometriosis\n. Eur J Obstet Gynecol Reprod Biol. 2023, 280:174-8. \n10.1016/j.ejogrb.2022.12.004\n20\n. \nDior UP, Reddington C, Cheng C, Levin G, McInerney C, Moss A, Healey M: \nLower gastrointestinal function\nafter surgery for deep endometriosis: a prospective cohort study\n. Int J Gynaecol Obstet. 2023, 160:280-8.\n10.1002/ijgo.14350\n21\n. \nMeuleman C, D'Hoore A, Van Cleynenbreugel B, Beks N, D'Hooghe T: \nOutcome after multidisciplinary CO2\nlaser laparoscopic excision of deep infiltrating colorectal endometriosis\n. Reprod Biomed Online. 2009,\n18:282-9. \n10.1016/S1472-6483(10)60267-2\n22\n. \nGreen IC, Burnett T, Famuyide A: \nPersistent pelvic pain in patients with endometriosis\n. Clin Obstet Gynecol.\n2022, 65:775-85. \n10.1097/GRF.0000000000000712\n23\n. \nMcNamara HC, Frawley HC, Donoghue JF, et al.: \nPeripheral, central, and cross sensitization in\nendometriosis-associated pain and comorbid pain syndromes\n. Front Reprod Health. 2021, 3:729642.\n10.3389/frph.2021.729642\n24\n. \nJones G, Kennedy S, Barnard A, Wong J, Jenkinson C: \nDevelopment of an endometriosis quality-of-life\ninstrument: the Endometriosis Health Profile-30\n. Obstet Gynecol. 2001, 98:258-64. \n10.1016/s0029-\n7844(01)01433-8\n25\n. \nHarada T, Taniguchi F, Kitajima M, et al.: \nClinical practice guidelines for endometriosis in Japan (The 3rd\nedition)\n. J Obstet Gynaecol Res. 2022, 48:2993-3044. \n10.1111/jog.15416\n \n2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919\n13\n of \n13","source_license":"CC0","license_restricted":false}